|

GSK5764227 Clinical Trials

5 actively recruiting trials across 3 locations

No change since May 2026

Pipeline

Phase 1: 2Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • GlaxoSmithKline4
  • University Health Network, Toronto1

Indications

  • Cancer5
  • Neoplasms2
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1
  • Neoplasms, Lung1
  • Gastrointestinal Neoplasms1

Other2 trials

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Phase 3

Los Alamitos, California1 trial

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

GSK Investigational Site

Phase 1/2

Stanford, California1 trial

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

GSK Investigational Site

Phase 1

Lake Success, New York1 trial

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

GSK Investigational Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.